Opus Genetics, Inc. (FRA:R3X1)

Market Cap	198.44M +441.2%
Revenue (ttm)	12.47M +74.6%
Net Income	-58.13M
EPS	-1.17
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	75
Open	2.985
Previous Close	3.015
Day's Range	2.850 - 3.000
52-Week Range	0.575 - 3.275
Beta	n/a
RSI	60.09
Earnings Date	Mar 30, 2026

About Opus Genetics

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutation...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 18
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: R3X1

Financial Performance

In 2024, Opus Genetics's revenue was $10.99 million, a decrease of -42.30% compared to the previous year's $19.05 million. Losses were -$57.53 million, 476.1% more than in 2023.

Financial numbers in USD